Preface - ESMO IO 2022 Matteo Simonelli, MD, Department of Biomedical Sciences, Humanitas University, Milan, Italy & Oncology Department, IRCCS ­Humanitas Research Hospital, Milan, Italy Dear Colleagues, The ESMO Immuno-Oncology Congress took place in Geneva, Switzerland, and virtually from 7th to 9th December 2022. In total, more than 2,000 participants from more than 100 countries attended one of the 31 sessions featuring over 249 presented abstracts, 6 late breaking abstracts, 6 prof

New strategies with PD-1/PD-L1 blockade in lung cancer Small-cell lung cancer (SCLC) accounts for about 15 % of all diagnosed cases of lung cancer and is characterized by a high proliferative rate, an early development of widespread metastases and a poor prognosis [1]. The five-year survival rate is less than 7 % [2]. More than two-thirds of patients with this highly aggressive neuroendocrine tumor are diagnosed with advanced or extensive-stage disease (ES-SCLC) [3]. For more than two decades

Emerging therapies in solid tumors BMS-986253 plus nivolumab and ipilimumab Interleukin-8 (IL-8), also known as chemokine (C-X-C motif) ligand 8, is a pro-inflammatory chemokine that ­exerts direct pro-tumorigenic effects ­primarily by recruiting immunosuppressive cells into the tumor microenvironment such as neutrophils and myeloid-derived suppressor cells. IL-8 has also been shown to promote cancer progression and resistance to therapy, by inducing angiogenesis, epithelial-mesenchymal tran

Conventional chemotherapy combined with PD-1/PD-L1 Neoadjuvant camrelizumab plus albumin-bound paclitaxel and cisplatin Neoadjuvant chemotherapy (CT), which has been the standard-of-care for resectable NSCLC, resulted only in modest survival benefits of approximately 5 %.

Preface © Andrea Enderlein Prof. Wolf H. Fridman – Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France Dear Colleagues, The ESMO Immuno-Oncology Congress 2021 took place online from 8th to 11th December 2021.

Immune checkpoint blockade combined with chemotherapy in solid tumors Pooled analysis of PD-1 inhibitor versus bevacizumab in NSCLC Non-small cell lung cancer (NSCLC) is a severe disease with poor outcomes since the majority of patients present with stage IV disease at diagnosis [1].

Established and novel chemo-free combinations in immuno-oncology LEAP-007: pembrolizumab plus lenvatinib in first-line NSCLC Immunotherapy was the major breakthrough in the treatment of lung cancer in the past years [1].